SCHEMBL25754649

SCHEMBL25754649

CC#CCCN1CCC(NC2CCCCC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
THRB P10828 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GNAI3 P08754 1/20 0.38
GNAO1 P09471 1/20 0.38
GNAI1 P63096 1/20 0.38
CXCR3 P49682 1/20 0.36
RAD52 P43351 1/20 0.36
MAPT P10636 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP1A2 P05177 1/20 0.32
SIGMAR1 Q99720 2/20 0.31
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754631 0.87 ALDH1A1 (0.40) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL17552000 0.76 HRH3 (0.48) MAPTHRH3
SCHEMBL25754561 0.75 SIGMAR1 (0.41) ALDH1A1SIGMAR1
SCHEMBL25754557 0.71 ACHE (0.35) HRH3
SCHEMBL7426080 0.70 ALDH1A1 (0.44) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL13200791 0.69 ALDH1A1 (0.60) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL23807237 0.69 GNAI3 (0.41) L3MBTL1GNAI3GNAO1GNAI1
SCHEMBL12519917 0.68 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL20846483 0.68 HRH3 (0.42) ALDH1A1HRH3NPSR1SIGMAR1
SCHEMBL13888146 0.67 ALDH1A1 (0.55) ALDH1A1HSD17B10THRBATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 ALDH1A1 2539/4885HSD17B10 2815/4885THRB 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.